Original Research
Saturday, November 11, 2023
11:30 AM–01:00 PM
Abstract
Introduction: Angiotensin II type 1 receptor antibody is known to associate with antibody mediated rejection as well as the poor overall kidney graft outcomes.
Research Question or Hypothesis: This study is to determine the effect of AT1R-Ab positivity on the clinical outcomes of kidney graft in a single center. It is hypothesized that there are no differences in the graft outcomes between the patients with AT1R-Ab positivity and control groups.
Study Design: This is a retrospective, observational study.
Methods: Among a total of 130 kidney graft recipients at the St. Joseph Medical Center from 2018 to 2022, a total of twenty one patients with pre-transplant AT1R-ab positivity were identified (study group) and the same number of risk factor matched control group (age, sex, diabetes and number of transplant) were selected. The biopsy data for graft rejection, eGFR, and systemic blood pressure (SBP) at baseline, 3-month, 6-month, 9-month, and 12-month were collected and compared between two groups. In terms of statistics, Chi square test and a student t test were used for the categorical data and for the continuous data and p value <0.05 is considered to be significant.
Results: The incidences of acute graft rejection were 30 % in the study group and 9% in the control group (p= 0.029). eGFRs (ml/min) were significantly lower in the AT1R-ab positive patients compared with the control group except for at baseline; the study group vs. the control group (30.9±13.5 vs.39.1±13.5, P=0.054), at 3 months (54.2±18.5 vs. 67.3±14.6, p= 0.015), 6 months (53.6±21vs.67.9±14.0, p= 0.014), 9 months (56.0±21.2vs.70.2±15.8, p= 0.014), and at 12 months i(52.0±20.9 vs.68.1±16.4, p= 0.008). In the case of SBP (mmHg), it was significantly higher in the study group compared to the control group.
Conclusion: This study demonstrates that pre-transplant AT1R-Ab positivity results in the poor graft outcomes during 12 months post-kidney transplant.
Presenting Author
Nare Gevorgyan Pharm.D.Western University of Health Sciences
Authors
David Min PharmD, MS
Western University of Health Sciences
Yasir Qazi MD
Providence St. Joseph Medical Center, Orange, CA